Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer

Carol Aghajanian,Barbara Goff,Lawrence R Nycum,Yan V Wang,Amreen Husain,Stephanie V Blank

Gynecologic Oncology（2015）

引用 261|浏览24

暂无评分

摘要

•Median follow-up for OS was 57.5months in the updated analyses.•Results of the updated OS analyses were consistent with interim analyses.•Bevacizumab did not improve OS when added to GC therapy in this patient population.

查看译文

关键词

OCEANS,Ovarian cancer,Bevacizumab,Overall survival,Safety

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要